Jade Biosciences (JBIO) Common Equity (2020 - 2026)
Jade Biosciences' (JBIO) quarterly Common Equity came in at $296.5 million in Q1 2026, up 455.0% YoY from $53.4 million in Q1 2025, and down 10.84% on a QoQ basis from $332.5 million in Q4 2025.
Jade Biosciences (JBIO) Common Equity (2020 - 2026) Analysis & Trends
Jade Biosciences (JBIO) has 7 years of Common Equity data on file, last reported at $296.5 million in Q1 2026.
- Quarterly Common Equity rose 455.0% year-over-year to $296.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $296.5 million (up 455.0% YoY) and the FY2025 annual result came in at $332.5 million, up 810.52% from the prior year.
- Common Equity fell to $296.5 million in Q1 2026, from $332.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $332.5 million in Q4 2025 to a low of -$83.5 million in Q1 2025.
- A 5-year average of $118.9 million and a median of $126.7 million in 2022 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 34320.03% in 2025, down 191.87% in 2025.
- Tracing JBIO's Common Equity over 5 years: stood at $126.7 million in 2022, then slipped by 13.64% to $109.5 million in 2023, then slumped by 142.76% to -$46.8 million in 2024, then soared by 810.52% to $332.5 million in 2025, then dropped by 10.84% to $296.5 million in 2026.
- The last three Common Equity figures came in at $296.5 million (Q1 2026), $332.5 million (Q4 2025), and $179.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Jade Biosciences | 1.57 Bn | 1.11 Bn | - | 439.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 439.92 Mn |
| Mar 31, 2026 | 296.46 Mn |
| Dec 31, 2025 | 332.52 Mn |
| Sep 30, 2025 | 179.35 Mn |
| Jun 30, 2025 | 201.56 Mn |
| Mar 31, 2025 | -83.51 Mn |
| Dec 31, 2024 | -46.80 Mn |
| Sep 30, 2024 | -16.86 Mn |
| Jun 30, 2024 | -589,000.00 |
| Mar 31, 2024 | 90.90 Mn |
| Dec 31, 2023 | 109.46 Mn |
| Sep 30, 2023 | 125.72 Mn |
| Jun 30, 2023 | 141.93 Mn |
| Mar 31, 2023 | 113.10 Mn |
| Dec 31, 2022 | 126.74 Mn |
| Sep 30, 2022 | 139.14 Mn |
| Jun 30, 2022 | 151.05 Mn |
| Mar 31, 2022 | 161.95 Mn |
| Dec 31, 2021 | 172.42 Mn |
| Sep 30, 2021 | 179.85 Mn |